Gemini Therapeutics Performance
| GMTXDelisted Stock | USD 17.95 0.05 0.28% |
The company retains a Market Volatility (i.e., Beta) of 1.55, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gemini Therapeutics will likely underperform. Gemini Therapeutics right now retains a risk of 0.0%. Please check out Gemini Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Gemini Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Gemini Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Gemini Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 4.8 M | |
| Total Cashflows From Investing Activities | 344 K |
Gemini |
Gemini Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,795 in Gemini Therapeutics on January 20, 2024 and sell it today you would earn a total of 0.00 from holding Gemini Therapeutics or generate 0.0% return on investment over 90 days. Gemini Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Gemini, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gemini Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gemini Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gemini Therapeutics, and traders can use it to determine the average amount a Gemini Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GMTX |
Based on monthly moving average Gemini Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gemini Therapeutics by adding Gemini Therapeutics to a well-diversified portfolio.
Gemini Therapeutics Fundamentals Growth
Gemini Stock prices reflect investors' perceptions of the future prospects and financial health of Gemini Therapeutics, and Gemini Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gemini Stock performance.
| Return On Equity | -0.35 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (34.25 M) | |||
| Shares Outstanding | 43.33 M | |||
| Price To Book | 0.68 X | |||
| EBITDA | (69.48 M) | |||
| Cash And Equivalents | 108.66 M | |||
| Cash Per Share | 2.51 X | |||
| Total Debt | 404 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 2.42 X | |||
| Cash Flow From Operations | (59.7 M) | |||
| Earnings Per Share | (1.58) X | |||
| Total Asset | 140.44 M | |||
About Gemini Therapeutics Performance
To evaluate Gemini Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Gemini Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Gemini Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Gemini Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Gemini's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration . Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Gemini Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.Things to note about Gemini Therapeutics performance evaluation
Checking the ongoing alerts about Gemini Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gemini Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gemini Therapeutics is not yet fully synchronised with the market data | |
| Gemini Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (71.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Gemini Therapeutics currently holds about 108.66 M in cash with (59.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| Over 88.0% of the company shares are owned by institutional investors |
- Analyzing Gemini Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gemini Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Gemini Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gemini Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gemini Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gemini Therapeutics' stock. These opinions can provide insight into Gemini Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Gemini Stock
If you are still planning to invest in Gemini Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemini Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Correlations Find global opportunities by holding instruments from different markets |